Cutaneous squamous cell carcinoma: from biology to therapy

R Corchado-Cobos, N García-Sancha… - Advances in Surgical …, 2023 - taylorfrancis.com
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in
humans, with an estimated incidence of 1 million cases each year in the United States …

[HTML][HTML] Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis

C Boman, I Zerdes, K Mårtensson, J Bergh… - Cancer Treatment …, 2021 - Elsevier
Introduction Programmed cell death ligand 1 (PD-L1) expression is predictive for benefit
from immunotherapy in several human malignancies including triple negative breast cancer …

Sprod for de-noising spatially resolved transcriptomics data based on position and image information

Y Wang, B Song, S Wang, M Chen, Y Xie, G Xiao… - Nature …, 2022 - nature.com
Spatially resolved transcriptomics (SRT) provide gene expression close to, or even superior
to, single-cell resolution while retaining the physical locations of sequencing and often also …

PD-L1 status in breast cancer: Current view and perspectives

S Vranic, FS Cyprian, Z Gatalica, J Palazzo - Seminars in cancer biology, 2021 - Elsevier
Breast cancer was traditionally not considered a particularly immunogenic tumor. However,
recent developments have shown that some aggressive triple-negative breast cancers are …

Current understandings and clinical translation of nanomedicines for breast cancer therapy

Y Jiang, Z Jiang, M Wang, L Ma - Advanced drug delivery reviews, 2022 - Elsevier
Breast cancer is one of the most frequently diagnosed cancers that is threatening women's
life. Current clinical treatment regimens for breast cancer often involve neoadjuvant and …

Programmed death-ligand 1 (PD-L1) as immunotherapy biomarker in breast cancer

M Núñez Abad, S Calabuig-Fariñas, M Lobo de Mena… - Cancers, 2022 - mdpi.com
Simple Summary Breast cancer (BC) is the most common malignant neoplasm in women
and one of the leading causes of cancer death in women worldwide. Programmed death …

Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis

Y Zou, X Hu, S Zheng, A Yang, X Li, H Tang, Y Kong… - …, 2021 - thelancet.com
Background Several biomarkers predict the efficacy of immunotherapy, which is essential for
selecting patients who would potentially benefit. Discordant status of these biomarkers …

[HTML][HTML] Targeting PD-1/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients

S Kumar, M Chatterjee, P Ghosh, KK Ganguly, M Basu… - Genes & …, 2023 - Elsevier
Maintaining the balance between eliciting immune responses against foreign proteins and
tolerating self-proteins is crucial for maintenance of homeostasis. The functions of …

Crosstalk between HER2 and PD-1/PD-L1 in breast cancer: from clinical applications to mathematical models

R Padmanabhan, HS Kheraldine, N Meskin, S Vranic… - Cancers, 2020 - mdpi.com
Breast cancer is one of the major causes of mortality in women worldwide. The most
aggressive breast cancer subtypes are human epidermal growth factor receptor-positive …

Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation

SK Parvathareddy, AK Siraj, IA Al-Badawi, A Tulbah… - Scientific Reports, 2021 - nature.com
Ovarian cancer (OC) is one of the most common gynecologic cancer, which has the worst
prognosis and highest mortality rate. The lack of curative treatment and the high relapse …